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Abstract
Background: The tumor response to preoperative radiotherapy of locally advanced rectal cancer
varies greatly, warranting the use of experimental models to assay the efficacy of molecular
targeting agents in rectal cancer radiosensitization. Histone deacetylase (HDAC) inhibitors, agents
that cause hyperacetylation of histone proteins and thereby remodeling of chromatin structure,
may override cell cycle checkpoint responses to DNA damage and amplify radiation-induced tumor
cell death.
Methods: Human colorectal carcinoma cell lines were exposed to ionizing radiation and HDAC
inhibitors, and cell cycle profiles and regulatory factors, as well as clonogenicity, were analyzed.
Results: In addition to G2/M phase arrest following irradiation, the cell lines displayed cell cycle
responses typical for either intact or defective p53 function (the presence or absence, respectively,
of radiation-induced expression of the cell cycle inhibitor p21 and subsequent accumulation of G1
phase cells). In contrast, histone acetylation was associated with complete depletion of the G1
population of cells with functional p53 but accumulation of both G1 and G2/M populations of cells
with defective p53. The cellular phenotypes upon HDAC inhibition were consistent with the
observed repression of Polo-like kinase-1, a regulatory G2/M phase kinase. Following pre-treatment
with HDAC inhibitors currently undergoing clinical investigation, the inhibitory effect of ionizing
radiation on clonogenicity was significantly amplified.
Conclusion: In these experimental models, HDAC inhibition sensitized the tumor cells to ionizing
radiation, which is in accordance with the concept of increased probability of tumor cell death
when chromatin structure is modified.
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Standard treatment of rectal cancer that by clinical or radi-
ological assessment reveals locally advanced growth
within the pelvis involves preoperative radiotherapy
aimed at down-staging the tumor, to facilitate subsequent
surgical excision [1,2]. However, tumor response to pre-
operative therapy varies greatly from pathological com-
plete response to lack of objective response, warranting
the use of experimental models to assay the efficacy of
molecular targeting agents in rectal cancer radiosensitiza-
tion.
The combination of radiotherapy and chemotherapy is
advocated primarily because of the independent effect of
each modality. Chemotherapeutics enhance radiocytotox-
icity by means of increasing the initial DNA damage,
inhibiting DNA repair, or slowing down cellular repopu-
lation during fractionated radiotherapy, which are mech-
anisms that essentially depend on cell cycle
synchronization of the tumor cell population [3]. Theo-
retically, such synchronization is achieved when sub-
lethal DNA damage is applied to the tumor cells, by
means of activation of signaling pathways that are rapidly
manifested as arrests at cell cycle checkpoints [4].
Massive insult on DNA, such as double-strand DNA
breaks following cellular exposure to ionizing radiation,
may induce checkpoint responses in essentially any phase
of the cell cycle [4], ultimately leading to the outcome of
cell survival if DNA is properly repaired or, if not, cell
death [5]. The signaling pathway via the tumor-suppressor
protein p53, the primary regulator of the G1 checkpoint, is
often defective in human solid tumors. In tumor cells with
intact p53 function, however, DNA damage leads to rapid
p53 stabilization and subsequent induction of the G1
phase inhibitor p21 [5]. The mechanism of DNA damage-
activated G2 checkpoint signaling, initiated by ATM,
involves inhibition of the enzymatic activity of Polo-like
kinase-1 (Plk1) and subsequent delay in activation of the
G2/M transition kinase [6]. We have previously found that
cell cycle arrest of breast carcinoma cell lines at the G2/M
boundary comprises repression of the gene for Plk1, PLK
[7-9].
A variety of pharmacological compounds, designed to tar-
get cell cycle regulatory mechanisms, have been shown to
override the DNA damage defense response that prevents
mitotic entry [10]. Such agents may have therapeutic
potential as radiosensitizers by facilitating cell death by
mitotic catastrophe, and a wide array of compounds are
undergoing clinical development [11].
Drugs that modify the cellular chromatin structure may
also radiosensitize tumor cells. Taxanes, which disrupt
chromatin structure and chromosome segregation in
mitotis, are currently utilized clinically as radiosensitizers
in treatment of non-small cell lung cancer and head-and-
neck cancer [12]. Cellular treatment with HDAC inhibi-
tors causes hyperacetylation of histone proteins, which
leads to remodeling of chromatin structure [13]. In addi-
tion to this, the pertubation by HDAC inhibitors of cell
cycle checkpoint signaling [14] might constitute the cellu-
lar mechanism by which these compounds enhance
tumor cell sensitivity to radiation treatment. Currently,
seven HDAC inhibitors are under investigation in clinical
trials [15].
In a previous report we compared cell cycle responses of a
human breast carcinoma cell line to ionizing radiation
and HDAC inhibition [7]. The cell line we used required
rather high concentrations of the HDAC inhibitor, tri-
chostatin A (TSA), to reveal histone acetylation. Moreover,
we chose to treat the cell line with a high radiation dose
(8 Gy) to possibly achieve clearly defined effects on the
cell cycle phenotype. In these breast carcinoma cells, the
G2 phase responses to ionizing radiation were closely sim-
ilar to those observed upon TSA treatment [7].
The frequency of TP53 mutations in colorectal cancer is
40–50% [16]. Hence, in the present study we have com-
pared colorectal carcinoma cell lines with wild-type or
mutated TP53, to evaluate the use of HDAC inhibitors in
combination with ionizing radiation in rectal cancer. As
valid experimental conditions for rectal cancer therapy,
we measured inhibitory effects of ionizing radiation on
clonogenicity after exposure to radiation doses of 2 or 5
Gy, which are fractionation doses used in preoperative
treatment of locally advanced disease [1,17], and the pos-
sible radiosensitization by suberoylanilide hydroxamic
acid (SAHA; currently licensed as vorinostat) or the ben-
zamide MS-275, which are HDAC inhibitors in clinical
development [15].
Methods
Cell lines and experimental treatments
The origin of the human colorectal carcinoma cell lines is
delineated previously [18]. The HCT116 and SW620 cell
lines were purchased from ATCC (Manassas, VA, USA).
The Co115 cell line was obtained from Dr. B. Sordat
(Swiss Institute of Experimental Cancer Research, Epalin-
ges, Switzerland), whereas the KM20L2 cell line was pro-
vided by Dr. M. R. Boyd (National Cancer Institute,
Frederick, MD, USA). All cell lines were cultured in RPMI
1640 medium supplemented with 10% fetal bovine
serum and 2.0 mM glutamine. High-energy radiation
from a 60Co source was delivered at a rate of approxi-
mately 0.6 Gy/minute. The unirradiated control cells were
simultaneously placed in room temperature to obtain
comparable conditions. The commercially available
HDAC inhibitors TSA and SAHA were obtained fromPage 2 of 10
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HDAC inhibitor MS-275 was a generous gift from Scher-
ing AG (Berlin, Germany).
Flow cytometry analysis
Cells were harvested in ice-cold phosphate-buffered
saline, centrifuged, and fixed in 100% methanol. To deter-
mine the fractions of cells in G1, S, and G2/M phases from
the cell cycle distribution, the cells were stained with 1.5
μg/ml Hoechst 33258 in phosphate-buffered saline and
analyzed in a FACStar+ flow cytometer (Becton Dickin-
son, San Jose, CA, USA), as described previously [8].
Western blot analysis
Protein expression was measured by means of standard
Western blot technique, as described previously [8], and
all experiments were performed two or three independent
times. The membranes were immunostained with desig-
nated primary antibodies obtained from Zymed Labora-
tories Inc. (San Francisco, CA, USA), Santa Cruz
Biotechnology (Santa Cruz, CA, USA), Calbiochem/
Merck Biosciences Ltd. (Nottingham, UK), or Upstate
(Lake Placid, NY, USA). These were anti-Plk1 (Zymed;
33–1700), anti-p53 (SC-6243), anti-Cyclin D1 (SC-
20044), anti-p21 (SC-6246), anti-α-tubulin (Calbio-
chem; CP06), anti-acetyl-histone H3 (Upstate; 06–599),
and anti-acetyl-histone H4 (Upstate; 06–866), respec-
tively.
Northern blot analysis
Expression of RNA was measured by means of standard
Northern blot technique, as described previously [8]. The
human cDNA clone for PLK was obtained from RZPD
Deutsches Ressourcenzentrum für Genomforschung
GmbH (Berlin, Germany). The human cDNA probe for
CCND1 was a gift from Dr. D. Beach (Howard Hughes
Medical Institute, Cold Spring Harbor, NY, USA), and the
human cDNA probe for CDKN1A was a gift from Dr. B.
Vogelstein (The John Hopkins University School of Med-
icine, Baltimore, MD, USA). To evaluate the amounts of
RNA loaded, the filters were rehybridized to a kinase-
labeled oligonucleotide probe complementary to nucle-
otides 287–305 of human 18S rRNA.
Assessment of clonogenicity
Clonogenic regrowth efficiency was determined by plat-
ing single cells suspended in medium. The cells were left
for 6 hours to allow attachment to the plastic before the
medium was replaced by media with or without HDAC
inhibitors. Following 18 hours incubation, the media
were changed to fresh medium (without any drug) and
the cells immediately irradiated. The appropriate plating
density was aimed to produce 20–40 surviving colonies in
each well of six-well culture plates. After incubation for 7
days, the cell colonies were fixed and stained with 0.1%
crystal violet. Colonies of ≥ 50 cells were counted for com-
puting of surviving fraction. At least three parallel samples
were scored in three to five repetitions performed for each
treatment condition.
Results
Cell cycle responses to ionizing radiation
Four colorectal carcinoma cell lines (HCT116, Co115,
SW620, and KM20L2) were initially observed for 48 hours
for cell cycle responses to ionizing radiation (8 Gy). As
seen from Figure 1, the HCT116 and SW620 cell lines dis-
played typical patterns of cell cycle redistribution for cells
with intact (HCT116) or defective (SW620) p53 function,
respectively. Irradiated HCT116 cells were arrested in G1
phase shortly after DNA damage, while S phase cells were
progressing into G2/M phase (observe the S phase shift at
6–12 hours). A distinct accumulation of G2/M phase cells
was seen during the remaining observation period (Figure
1, upper panel). In contrast, radiation exposure of the
SW620 cell line resulted in depletion of G1 phase cells but
instead G2/M phase delay, which apparently persisted for
a period 24 hours or longer after DNA damage but did not
seem to be plenary, as a new G1 population was observed
after 24 hours (Figure 1, third panel from top).
The responses of regulatory proteins of the G1 and G2/M
cell cycle phases to ionizing radiation were also followed
(Figure 2) to observe whether these might correlate to the
changes in cell cycle redistribution. In irradiated HCT116
cells, rapid induction of the G1 phase inhibitor p21 and its
mRNA (CDKN1A) was observed, consistent with the
immediate stabilization of p53 following DNA damage.
Interestingly, expression of the principal G1 phase cyclin,
Cyclin D1, seemed to be up-regulated by ionizing radia-
tion as well, but with much lower amplitude and slower
kinetics than p21. The SW620 cells showed complete
absence of G1 checkpoint-activated characteristics (p53
and p21 responses), and Cyclin D1 was rather down-reg-
ulated, though transiently. In contrast to what we have
previously observed in various breast carcinoma cell lines,
in which expression of the G2/M phase kinase Plk1 has
been found to be transiently down-regulated following
radiation exposure [7-9,19], Plk1 expression was found to
be increased above control level in irradiated SW620 cells
and possibly also in the HCT116 counterparts (Figure 2).
Following radiation exposure of the wild-type TP53
Co115 cell line, the percentage of G2 phase cells was grad-
ually increasing, while a distinct G1 population was main-
tained during the observation period (Figure 1, second
panel from top). In these cells, p53 stabilization and
resulting induction in CDKN1A mRNA and p21 protein as
well as repression of PLK mRNA and Plk1 protein were
seen (Figure 2). These response profiles to DNA damage
were highly correlated to the observed changes in cellPage 3 of 10
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of G1 checkpoint protein responses but increased Plk1
expression upon irradiation (Figure 2). As seen from the
lower panel of Figure 1, this cell line showed distinct DNA
damage-induced G2/M phase arrest but with a small G1
population present during the entire observation period.
Cell cycle responses to TSA
Since cell cycle responses associated with intact or defec-
tive p53 function were typically displayed by the HCT116
and SW620 cell lines, respectively, effects of HDAC inhi-
bition by TSA were analyzed in these particular cell lines.
Tumor cell sensitivity to HDAC inhibitors may vary along
a wide concentration range and should be considered
highly cell line-specific. Thus, effects of increasing concen-
trations of TSA (10–300 nM) on histone acetylation status
of the HCT116 and SW620 cell lines were determined. As
seen from Figure 3, levels of acetylated core histones H3
and H4 were substantially induced after 12 and 24 hours
incubation with TSA concentrations above 30 nM, sug-
gesting that TSA in concentrations of 30–100 nM for a
treatment period of 12–24 hours might be appropriate for
further mechanistic studies.
Pharmacological inhibition of HDAC activity has been
shown to cause cell cycle arrest in the G2/M phase in a
variety of tumor cell lines [7,20-23], resembling DNA
damage-induced G2 checkpoint response to ionizing radi-
ation. Interestingly, TSA treatment (100 nM) of the
HCT116 and SW620 cell lines for a period of 0–24 hours
resulted in cell cycle responses highly different from the
irradiated phenotypes. In the HCT116 cells, complete
depletion of G1 phase cells followed by arrest of cells in
G2/M phase was observed, before a new G1 population
appeared after 24 hours of TSA incubation (Figure 4,
upper panel). Moreover, TSA-treated SW620 cells were
instantly arrested in G1 phase, while S phase cells were
gradually progressing into G2/M phase. A distinct accu-
mulation of G2/M phase cells was seen during the entire
observation period (Figure 4, lower panel). Hence, in
both HCT116 and SW620 cells, TSA treatment was associ-
ated with redistribution of cell populations into radiosen-
sitive cell cycle phases (G1 or G2/M).
Consistent with the G2/M phase accumulation of both
cells lines, TSA-dependent Plk1 repression was seen (Fig-
ure 5), similar to what we have observed previously in a
breast carcinoma cell line [7]. From below detection, p21
expression seemed to be induced 24 hours after addition
of TSA to the HCT116 cells. In contrast, p53 expression
appeared to be repressed in the SW620 cells 24 hours after
TSA addition (Figure 5). These TSA-dependent character-
istics have previously been found to coincide in breast car-
cinoma cells [7]. Apart from PLK mRNA, apparent TSA-
associated changes in mRNA levels did not convincingly
translate into the respective cell cycle proteins (Figure 5).
Ionizing radiation and HDAC inhibition by TSA – 
clonogenicity
Next, the HCT116 and SW620 cell lines were exposed to
therapeutically utilized doses of ionizing radiation (2 and
5 Gy) to determine clonogenic survival. Cell cycle
responses to 5 Gy of ionizing radiation, assessed as time-
dependent redistribution of cell cycle phases and expres-
sion of corresponding regulatory proteins (data not
Cell cycle profiles following exposure to ionizing radiation (IR)Figure 1
Cell cycle profiles following exposure to ionizing radi-
ation (IR). Four colorectal carcinoma cell lines (HCT116, 
Co115, SW620, and KM20L2) were exposed to 8 Gy of IR 
(+) and further incubated for the indicated time periods 
before cellular DNA contents were determined by flowcy-
tometry analysis gated for Hoechst 33258 fluorescence. Cells 
with DNA contents characteristic for G1 and G2/M phase 
cells were found in channel numbers ~50 and 90–100 along 
the x axes, respectively. Scales indicating cell counts (y axes) 
are provided.Page 4 of 10
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8 Gy described above. As shown by Figure 6, the HCT116
cells showed surviving fractions of ~0.4 and 0.07–0.1 with
2 and 5 Gy, respectively, whereas relative SW620 colony
formation upon exposure to those doses were ~0.6 and
~0.15, respectively.
Moreover, the possible radiosensitizing effect of TSA,
essentially by amplifying the inhibitory effect of ionizing
radiation on clonogenicity, was measured. Based on the
histone acetylation data (Figure 3) and the observed redis-
tribution of cell cycle phases (Figure 4), we chose to ana-
lyze the cell lines upon incubation with 30 and 100 nM
concentrations of TSA for 18 hours before the HDAC
inhibitor was removed and the cells irradiated. With these
incubation conditions, unirradiated HCT116 cells
showed surviving fractions of ~0.5 and ~0.35 with 30 and
100 nM TSA, respectively, whereas relative SW620 colony
formation was ~0.6 with both TSA concentrations. As seen
from Figure 6, the cytotoxic effect of ionizing radiation on
both HCT116 and SW620 cell lines seemed to be ampli-
fied by TSA, but interestingly more pronounced with the
lower concentration.
Ionizing radiation and HDAC inhibition by SAHA or MS-
275 – clonogenicity
Finally, the HCT116 cells were also treated with two
HDAC inhibitors that are currently in clinical investiga-
tion (SAHA and MS-275) to determine if those might
cause radiosensitization. As shown by Figure 7, levels of
acetylated histones H3 and H4 were induced in a concen-
tration-dependent manner after 12 and 24 hours exposure
to SAHA or MS-275 (both 0.25–5.0 μM).
Theoretically, chemotherapeutics enhance radiocytotoxic-
ity within concentration ranges that apply sub-lethal DNA
damage to the tumor cells. Upon incubation of the
HCT116 cells for 18 hours, 10–25% inhibition of colony
formation was achieved with SAHA and MS-275 within
low micromolar concentration ranges (0.50–1.0 μM and
1.0–2.0 μM, respectively). And as seen from Figure 8, clo-
nogenicity of irradiated HCT116 cells was significantly
reduced by both compounds under these incubation con-
ditions.
Discussion
In this report we have compared cell cycle response pro-
files of human colorectal carcinoma cell lines to ionizing
Cell cycle regulatory factors following exposure to ionizing radiation (IR)Figure 2
Cell cycle regulatory factors following exposure to ionizing radiation (IR). Four colorectal carcinoma cell lines 
(HCT116, Co115, SW620, and KM20L2) were exposed (+) to 8 Gy of IR, or left unexposed (-), and further incubated for the 
indicated time periods before analysis. Upper panel: Protein expression levels of Plk1, p53, Cyclin D1, and p21 were analyzed 
by Western blot immunostaining, using α-tubulin as protein loading control. Lower panel: mRNA expression levels of PLK, 
CCND1, and CDKN1A were analyzed by Northern blot hybridization, using 18S rRNA as RNA loading control.Page 5 of 10
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phase arrest following radiation exposure, the cell lines
displayed cell cycle responses typical for either intact or
defective p53 function. In contrast to the profiles induced
by irradiation, HDAC inhibition was associated with com-
plete depletion of the G1 phase population of cells with
functional p53 but accumulation of both G1 and G2/M
phase populations of cells with defective p53. Moreover,
histone acetylation was followed by significant reduction
in clonogenic regrowth of irradiated cells, irrespective of
p53 status. This observation is in accordance with the con-
cept of increased probability of tumor cell death when the
chromatin structure is modified.
Each cell line's p53 status was also confirmed by sequence
analysis of the TP53 gene, by means of methodology
described previously [7]. In both cell lines with TP53
mutation (SW620 and KM20L2), a base substitution of A
for a G nucleotide in codon 273, resulting in change of
amino acid Arg to His, was detected (data not shown).
According to the International Agency for Research on
Cancer's TP53 Mutation Database [24], this particular
base substitution represents ~5% of all TP53 mutations
recorded in colorectal carcinomas. The frequency of muta-
tions in the hotspot codon 273 in an international cohort
of colorectal carcinoma patients was recently reported to
be 8% [25], which may be regarded as a substantial frac-
tion of patients with TP53-mutated colorectal tumors.
In a variety of tumor cell models, pharmacological inhibi-
tion of HDAC activity has been shown to cause redistribu-
tion of cell cycle profiles resembling G2 checkpoint
responses to DNA damage [7,20-23]. Although accumula-
tion in G1 phase has been reported [22,23,26,27], induc-
tion of the G1 phase inhibitor p21 and concomitant
hypophosphorylation of the retinoblastoma protein
upon HDAC inhibition have been shown to occur with-
out subsequent G1 checkpoint arrest [20]. Our findings do
not clarify the issue of whether p21 may be involved. In
the SW620 cells, TSA treatment was associated with main-
tained G1 population in the absence of any p21 expres-
sion. Furthermore, the finding that a G1 population
reappeared in TSA-treated HCT116 cells is more likely due
to release of cells arrested in G2/M phase than to a concur-
rent p21 induction.
Although p21 as well as the principal G1 phase cyclin, Cyc-
lin D1, are considered targets for regulation by HDAC
inhibition [28-30], regulatory responses of these cell cycle
factors to TSA were not convincingly displayed by
HCT116 or SW620 cells. In contrast, repression of the G2/
M phase kinase Plk1 was clearly observed in both TSA-
treated cell lines, consistent with the G2/M phase accumu-
Cell cycle profiles upon TSA treatmentFigure 4
Cell cycle profiles upon TSA treatment. The HCT116 
and SW620 cell lines were treated (+) with 100 nM TSA and 
further incubated for the indicated time periods before cellu-
lar DNA contents were determined by flow cytometry analy-
sis gated for Hoechst 33258 fluorescence. Cells with DNA 
contents characteristic for G1 and G2/M phase cells were 
found in channel numbers ~50 and 90–100 along the x axes, 
respectively. Scales indicating cell counts (y axes) are pro-
vided.
Histone acetylation by TSAFigure 3
Histone acetylation by TSA. The HCT116 and SW620 
cell lines were treated with TSA in increasing concentrations, 
and protein extracts prepared after 12 and 24 hours of incu-
bation were analyzed by Western blot immunostaining with 
antibodies against acetylated histones H3 (acetyl-H3) and H4 
(acetyl-H4). α-tubulin was measured as protein loading con-
trol.Page 6 of 10
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mRNA expression is in accordance with our previous find-
ing [7]. PLK is among several genes, encoding mitotic reg-
ulators, of which mRNA expression is down-regulated
following activation of the G2 checkpoint [31]. Apart from
the Co115 cell line and contrary to our observations in
various breast carcinoma cells lines [7-9,19], however,
Plk1 was found to be up-regulated rather than down-reg-
ulated upon irradiation.
In tumor cell lines, cytotoxicity of chemotherapeutics and
the anti-Her2 antibody trastuzumab has been found
increased by the presence of SAHA and MS-275
[21,32,33]. Recently, MS-275 was also shown to sensitize
tumor cell lines to the growth-inhibitory effect of retinoic
acid [34]. Among HDAC inhibitors in clinical investiga-
tion, five have been reported to act as radiosensitizers in
preclinical models [26,35-40]. Interestingly, in animal
models, topical skin application of HDAC inhibitors sig-
nificantly suppressed cutaneous side effects of radiother-
apy [41], suggesting that the contemporary approach of
molecularly targeted therapy may be utilized to increase
the therapeutic ratio between the tumor and surrounding
normal tissues in radiotherapy. To our knowledge, the
present report is the first to study HDAC inhibition as
radiosensitizing strategy with therapeutically relevant
radiation doses in colorectal cancer.
In contrast to what was observed with SAHA and MS-275,
a threshold concentration of TSA (30–100 nM) seemed to
be necessary to obtain cellular acetylation of core histones
H4 and H3. Histone acetylation was clearly present with
TSA modulates clonogenic regrowth upon cellular exposure to ionizing radiati  (IR)Figure 6
TSA modulates clonogenic regrowth upon cellular 
exposure to ionizing radiation (IR). The HCT116 and 
SW620 cell lines were exposed to increasing IR doses with-
out (❍) or following pre-treatment for 18 hours with TSA in 
concentrations of 30 nM (■) or 100 nM (▲), to determine 
relative colony formation compared to the unirradiated situ-
ation (mean ± SEM, n = 3).
Cell cycle regulatory factors upon TSA treatmentFigure 5
Cell cycle regulatory factors upon TSA treatment. 
The HCT116 and SW620 cell lines were treated (+) with 
100 nM TSA, or left untreated (-), and further incubated for 
the indicated time periods before analysis. Upper panel: Pro-
tein expression levels of Plk1, p53, Cyclin D1, and p21 were 
analyzed by Western blot immunostaining, using α-tubulin as 
protein loading control. Lower panel: mRNA expression lev-
els of PLK, CCND1, and CDKN1A were analyzed by Northern 
blot hybridization, using 18S rRNA as RNA loading control.Page 7 of 10
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hours, whereas with 100 nM, hyperacetylation was main-
tained after 24 hours. Identical observations were done in
other colorectal carcinoma cell lines (data not shown).
Yet, following pre-treatment for 18 hours, the lower TSA
concentration (30 nM) was found to sensitize both cell
lines (HCT116 and SW620) to the inhibitory effect of ion-
izing radiation on clonogenicity, while the higher concen-
tration (100 nM) seemed less efficacious. A similar
phenomenon has been reported after experimental in vivo
use of MS-275, as inhibition of osteolytic bone metastases
seemed to be more efficient with the lower therapy dose
[42]. It has previously been shown that TSA also acts via
mechanisms involving acetylation of non-histone pro-
teins, which might be of consequence for TSA-induced
cytotoxicity [22]. Moreover, it has been suggested that dif-
ferent classes of HDAC inhibitors may cause differential
protein acetylation and, to a certain degree, differential
gene expression [43,44]. Such differences in effector
mechanisms might account for the apparent feature of
TSA contra SAHA and MS-275 to whether the histone
acetylation status might directly predict the compounds'
efficacy of sensitizing the tumor cells to DNA-damaging
therapy.
While TSA has shown excessive toxicity under in vivo con-
ditions, both SAHA and MS-275 have reached clinical
investigation [45-47]. The development and early thera-
peutic utilization of such compounds demand biomar-
ker(s) that may provide direct insight into their mode of
action. The complexity of effector mechanisms involved
with TSA is probably a main reason why this agent is not
feasible to monitor and, hence, use safely in the in vivo set-
ting.
Conclusion
There is strong scientific evidence that chromatin-remod-
eling drugs may radiosensitize tumor cells. The present
report indicates that histone acetylation is associated with
enhanced radiocytotoxicity in colorectal carcinoma cell
lines, irrespective of their TP53 mutation status. Whether
such information might translate into strategies to
Histone acetylation by SAHA and MS-275Figure 7
Histone acetylation by SAHA and MS-275. The HCT116 cells were treated with SAHA (upper panel) or MS-275 (lower 
panel) in increasing concentrations, and protein extracts prepared after 12 and 24 hours of incubation were analyzed by West-
ern blot immunostaining with antibodies against acetylated histones H3 (acetyl-H3) and H4 (acetyl-H4). α-tubulin was meas-
ured as protein loading control.Page 8 of 10
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further experimental approaches but hints, if anything, at
an appealing concept.
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